Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bf75d38625cb4bf6775d70bb9db2e3988> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bf75d38625cb4bf6775d70bb9db2e3988 NCIT_P378 "NCI" @default.
- Bf75d38625cb4bf6775d70bb9db2e3988 type Axiom @default.
- Bf75d38625cb4bf6775d70bb9db2e3988 annotatedProperty IAO_0000115 @default.
- Bf75d38625cb4bf6775d70bb9db2e3988 annotatedSource NCIT_C174563 @default.
- Bf75d38625cb4bf6775d70bb9db2e3988 annotatedTarget "A preparation of autologous CD4- and CD8-positive T-lymphocytes that have been transduced with a lentiviral vector (LV) expressing a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) CD19 that is fused to the intracellular cytoplasmic domain of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (CD3zeta), and linked to a truncated form of the human epidermal growth factor receptor 2 (HER2tG), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CD19CAR-4-1BB/CD3zeta-HER2tG-expressing CD4+/CD8+ T-lymphocytes SCRI-huCAR19v2 specifically target and bind to CD19-expressing neoplastic B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells and causes tumor cell lysis. CD19 is a B-cell-specific cell surface antigen that is overexpressed in B-cell lineage tumors. Incorporation of the costimulatory signaling domain increases human T-cell function, expansion, and survival. Devoid of both ligand binding domains and tyrosine kinase activity, the co-expressed HER2tG both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a trastuzumab-induced antibody dependent cellular cytotoxicity (ADCC) response." @default.